Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Rating of “Moderate Buy” from Brokerages

Assembly Biosciences, Inc. (NASDAQ:ASMB) has been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $45.60.

A number of equities analysts recently commented on the company. Wall Street Zen downgraded Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a research note on Tuesday, August 18th. UBS Group started coverage on Assembly Biosciences in a report on Tuesday, September 1st. They set a “buy” rating and a $52.00 target price on the stock. Guggenheim reiterated a “buy” rating and issued a $43.00 target price on shares of Assembly Biosciences in a research report on Thursday, May 28th. Finally, Mizuho set a $53.00 price target on Assembly Biosciences in a report on Tuesday, September 1st.

Hedge Funds Weigh In On Assembly Biosciences

A number of hedge funds have recently added to or reduced their stakes in ASMB. Informed Momentum Co LLC increased its stake in Assembly Biosciences by 1.6% during the fourth quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock valued at $1,004,000 after purchasing an additional 451 shares during the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Assembly Biosciences by 4.2% in the 4th quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock worth $672,000 after buying an additional 800 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Assembly Biosciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock worth $4,468,000 after buying an additional 1,212 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Assembly Biosciences by 4.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock worth $1,095,000 after buying an additional 1,634 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,319 shares during the period. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Price Performance

Shares of ASMB stock opened at $35.28 on Wednesday. The firm has a market cap of $718.30 million, a P/E ratio of 34.59 and a beta of 1.13. Assembly Biosciences has a 1-year low of $20.23 and a 1-year high of $39.71. The firm has a fifty day moving average of $29.55 and a two-hundred day moving average of $28.31.

Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.52. The company had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. On average, sell-side analysts expect that Assembly Biosciences will post 2.28 EPS for the current year.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.